首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1911892

精神藥物市場規模、佔有率和成長分析（按藥物類型、用途、治療層級、疾病、通路和地區分類）－2026-2033年產業預測

Psychotropic Drugs Market Size, Share, and Growth Analysis, By Drug Type (Aripiprazole, Brexipiprazole), By Application (Anti-Psychotics, Anti-Anxiety), By Therapeutic Class, By Disease, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月31日 | 出版商:

SkyQuest | 英文 188 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球精神藥物市場規模將達到 248 億美元，到 2025 年將達到 258.4 億美元，到 2033 年將達到 359.1 億美元，在預測期（2026-2033 年）內複合年成長率為 4.2%。

由於人們對心理健康問題的認知不斷提高，以及焦慮和憂鬱症盛行率的上升，全球精神藥物市場正經歷顯著成長。醫療保健服務的可近性提高推動了這一趨勢，而藥物研發技術的進步則進一步促進了市場擴張。政府對心理健康政策的支持以及診斷能力的提升，也提高了社會對精神疾病治療的接受度。此外，新興經濟體和全球範圍內可支配收入的成長也推動了精神藥物使用量的增加。這些因素共同造就了對精神藥物的強勁需求，並刺激市場持續擴張和創新，以滿足全球心理健康需求。

全球精神藥物市場促進因素

全球精神藥物市場主要受人們心理健康意識不斷提高的推動，而這種意識的提升主要得益於公共資訊宣傳活動和名人代言。人們對心理健康問題的認知不斷提高，導致診斷率上升，進而增加了對治療方案的需求。此外，政府的支持性政策和國際計劃旨在改善心理健康，也促進了人們獲得各種精神藥物，包括抗憂鬱症、抗焦慮藥物和抗精神病藥物。職場健康計畫也推動了這一趨勢，進一步增加了對有效心理健康解決方案的需求，尤其是在壓力水平較高的都市區。

全球精神藥市場面臨的限制

全球精神藥物市場面臨許多限制因素，監管機構強制要求進行嚴格的安全性和有效性評估，這將延長藥物上市流程。精神藥物的測試過程十分複雜，通常需要進行耗時且耗力的臨床試驗，且診斷結果往往帶有主觀性，導致研發成本高。此外，持續的上市後監測要求，特別是針對抗憂鬱劑自殺風險的安全監測，也進一步加重了企業的財務負擔。這些挑戰對中小型製藥公司構成了阻礙，它們可能難以有效應對將精神藥物推向市場所帶來的財務壓力。

全球精神藥物市場趨勢

全球精神藥物市場正迅速擁抱個人化醫療和生物標記驅動治療的新模式，這種模式提倡個人化治療，而非傳統的「一刀切」治療方法。基因檢測和藥物基因組學的創新使醫療專業人員能夠為精神疾病選擇最佳治療方法，顯著提高療效，同時最大限度地減少處方用藥過程中的猜測。 COMPASS Pathways 等公司正在引領迷幻療法的開發，並獲得了大量創業投資投資，並在醫療保健生態系統內建立了策略合作夥伴關係。這種向精準用藥的轉變有望改變精神健康治療的格局，從而改善患者預後並促進市場成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Johnson & Johnson（USA）
Pfizer Inc.（USA）
Eli Lilly and Company（USA）
AstraZeneca Plc（UK）
Otsuka Holdings Co., Ltd.（Japan）
Novartis AG（Switzerland）
Takeda Pharmaceutical Company Limited（Japan）
AbbVie Inc.（USA）
GlaxoSmithKline（GSK）（UK）
Bristol-Myers Squibb（BMS）（USA）
H. Lundbeck A/S（Denmark）
Janssen Pharmaceuticals（J&J Subsidiary）（USA）
Viatris Inc.（USA）
Teva Pharmaceutical Industries Ltd.（Israel）
Merck & Co., Inc.（USA）
Roche Holding AG（Switzerland）
Jazz Pharmaceuticals plc（Ireland）
Neurocrine Biosciences, Inc.（USA）
Sun Pharmaceutical Industries Ltd.（India）
Biogen Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35B2245

Global Psychotropic Drugs Market size was valued at USD 24.8 Billion in 2024 and is poised to grow from USD 25.84 Billion in 2025 to USD 35.91 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).

The global psychotropic drugs market is experiencing significant growth due to heightened awareness of mental health issues, alongside rising anxiety and depression rates. Enhanced access to healthcare services contributes to this trend, while advancements in drug development technologies further drive market expansion. Societal acceptance of psychiatric treatment is also on the rise, bolstered by government support for mental health initiatives and improved diagnostic capabilities. Additionally, emerging economies and increasing discretionary incomes worldwide are facilitating greater utilization of psychotropic medications. Collectively, these factors are creating a robust demand for psychotropic drugs, positioning the market for continued expansion and innovation in addressing mental health needs globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychotropic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychotropic Drugs Market Segments Analysis

Global Psychotropic Drugs Market is segmented by Drug Type, Application, Therapeutic Class, Disease, Distribution Channel and region. Based on Drug Type, the market is segmented into Aripiprazole, Brexipiprazole, Olanzapine, Peliperidone Palmitate, Clozapine, Quetiapine, Chlorpromazine, Risperidone, Paroxetine, Thioridazine, Fluvoxamine and Other Drug Types. Based on Application, the market is segmented into Anti-Psychotics, Anti-Anxiety, Mood Stabilizers, Antidepressants, Stimulants, Hypnotics, Antiepileptic Drugs and Other Applications. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is significantly propelled by the increasing awareness around mental health, largely fueled by public information campaigns and the support of high-profile celebrities. This growing recognition of mental health issues has led to higher rates of diagnosis and subsequently greater demand for treatment options. Additionally, supportive government policies and international initiatives aimed at mental health improvement have further facilitated access to various psychotropic medications such as antidepressants, anxiolytics, and antipsychotics. Workplace wellness programs also contribute to this trend, particularly in urban environments where people experience heightened stress, thus amplifying the need for effective mental health solutions.

Restraints in the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market faces significant restraints due to the rigorous safety and efficacy evaluations mandated by regulatory authorities, which can prolong the path to market entry. The testing process for psychiatric drugs is complex, often requiring intricate clinical trials that involve subjective diagnoses, contributing to high development costs. Furthermore, the ongoing requirements for post-marketing surveillance add financial burdens, particularly the need to monitor the safety of medications, such as anti-depressants concerning suicide risk. These challenges create obstacles for smaller pharmaceutical companies that may struggle to manage the financial demands associated with bringing psychotropic drugs to market effectively.

Market Trends of the Global Psychotropic Drugs Market

The Global Psychotropic Drugs market is increasingly embracing the paradigm of personalized medicine and biomarker-driven therapies, which prioritize tailored treatment approaches over traditional one-size-fits-all methods. Innovations in genetic testing and pharmacogenomics enable practitioners to select optimal treatments for mental health disorders, significantly enhancing efficacy while minimizing the guesswork involved in prescribing medications. Companies such as COMPASS Pathways are pioneering the development of psychedelic-based therapies, capturing substantial venture capital investments and forging strategic partnerships within the healthcare ecosystem. This shift toward precision pharmacotherapy is expected to reshape the landscape of mental health treatment, leading to improved patient outcomes and market growth.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Psychotropic Drugs Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Aripiprazole
Brexipiprazole
Olanzapine
Peliperidone Palmitate
Clozapine
Quetiapine
Chlorpromazine
Risperidone
Paroxetine
Thioridazine
Fluvoxamine
Other Drug Types

Global Psychotropic Drugs Market Size by Application & CAGR (2026-2033)

Market Overview
Anti-Psychotics
Anti-Anxiety
Mood Stabilizers
Antidepressants
Stimulants
Hypnotics
Antiepileptic Drugs
Other Applications

Global Psychotropic Drugs Market Size by Therapeutic Class & CAGR (2026-2033)

Market Overview
First Generation
Second Generation
Third Generation

Global Psychotropic Drugs Market Size by Disease & CAGR (2026-2033)

Market Overview
Schizophrenia
Bipolar Disorder
Unipolar Depression
Dementia
Other Diseases

Global Psychotropic Drugs Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Psychotropic Drugs Market Size & CAGR (2026-2033)

North America (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
- US
- Canada
Europe (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Application, Therapeutic Class, Disease, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Holdings Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (BMS) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H. Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Pharmaceuticals (J&J Subsidiary) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jazz Pharmaceuticals plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurocrine Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments